Skip to main content
Clinical Trials/NCT04594863
NCT04594863
Unknown
Not Applicable

The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer

Peking Union Medical College Hospital1 site in 1 country100 target enrollmentNovember 1, 2020
ConditionsCachexia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cachexia
Sponsor
Peking Union Medical College Hospital
Enrollment
100
Locations
1
Primary Endpoint
SIRT-6 expression
Last Updated
5 years ago

Overview

Brief Summary

The study is going to recruit patients with gastrointestinal cancer, collect clinical data and peripheral blood sample and possible fat samples. The expression of SIRT-6 in peripheral blood will be tested and connect with different status of cachexia of the patients. A mathematical model of the relationship between cachexia classification and SIRT-6 expression is going to constructed as anticipated.

Detailed Description

At the start of cancer develop, not all patients with gastrointestinal cancer manifest cachexia, it may be associated with SIRT-6 expression. This study will collect and test the peripheral blood sample of patients, use it as an important indicator of the degree of cachexia, and provide references for clinical drug intervention, prognosis and dietary intervention for cachexia patients. If possible, fat sample of the patients will be collected during surgery, and the adipose progenitor cells will be cultured to find the key target proteins by detecting differences in protein expression, changes in protein modification levels, and protein interactions.

Registry
clinicaltrials.gov
Start Date
November 1, 2020
End Date
June 1, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 90 years old, unlimited gender;
  • Patients who are diagnosed with gastrointestinal cancer for the first time and are planning to undergo further treatment;
  • Volunteer to participate and sign the informed consent form.

Exclusion Criteria

  • Women who are pregnant or lactate;
  • Patients with severe metabolic diseases; combined with cardiac function, liver and kidney dysfunction, acute myocardial infarction and acute stroke in the past 3 months , COPD acute onset respiratory failure and other serious medical diseases and patients who need hormone therapy

Outcomes

Primary Outcomes

SIRT-6 expression

Time Frame: 4 months

SIRT-6 expression tested by ELISA

Study Sites (1)

Loading locations...

Similar Trials